GCT is taking part in the CTAD Alzheimer Congress

GCT President, Dr. Jeffrey Apter is participating at the 13th Clinical Trials on Alzheimer’s Disease Congress (CTAD) which is held from 4th to 7th of November.

The congress brings worldwide leaders in the treatment of Alzheimer’s disease together, and is a perfect platform to share their expertise in the research of Alzheimer’s disease. Dr. Apter is KOL in psychiatry and has over 30 years of experience in clinical research focusing on Alzheimer’s disease.

Reach out to us at bd@gctrials.com if you would like to set up a meeting.

Updated: October 21, 2020

Permanent link: https://2022.gctrials.com/posts/gct-is-taking-part-in-the-ctad-alzheimer-congress/

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2021 Global Clinical Trials, LLC

All rights reserved.